Bisphosphonate-induced Osteonecrosis of the Jaws: Review, Clinical Implications and Case Report

Head and Neck Pathology

Volumn 1, Issue 2, 2007, Pages 156-164

  Suleman, Yusuf Farouk ^a   Meer, Shabnum ^a   Lurie, Russel ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Bisphosphonates; Jaws; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

AGED; BONE NECROSIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; PATHOLOGY; REVIEW;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; JAW DISEASES; OSTEONECROSIS;

EID: 77957361872     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-007-0022-5     Document Type: Review

References (48)

1. Fleish H, Schibler D, Maerki J, et al. Inhibition of aortic calcification by means of pyrophosphate and polyphosphates. Nature 1965;207:1300-1.
2. Papapoulos SE. Bisphosphonate actions: physical chemistry revisited. Bone 2006;38:613-6.
3. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006;64:917-23.
4. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonateinduced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35:588-93.
5. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.
6. Lenz JH, Steiner-Krammer B, Schmidt W, et al. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg 2005; 33:395-403.
7. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of aledronate. N Engl J Med 1996;335:1016-21.
8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
9. Migliorati CA. Bisphophonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
10. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
11. Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005;50: S4-13.
12. Zarychanski R, Elphee E, Walton P, et al. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006;81:73-5.
13. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52.
14. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
15. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90:1897-9.
16. Ott SM. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab 2001;86:1835-6.
17. Miller PD. Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis. Expert Opin Pharmacother 2003;4:2253-8.
18. Management of Osteoporosis in Postmenopausal Women: 2006 Position Statement of The North American Menopause Society. Menopause 2006;13(3):340-67.
19. Tonino RP, Santora A, Ross PD. Safety of long-term alendronate. J Clin Endocrinol Metab 2001;86:1835-6.
20. Assael LA. A time for perspective on bisphosphonates. J Oral Maxillofac Surg 2006;64:877-9.
21. Novartis Pharmaceuticals Corporation. Expert panel recommendation for the prevention, diagnosis and treatment of osteonecrosis of the jaw. 2005. Appendix 11. Available from: www.fda.gov/orhms/dockets/ac/05/briefing/2005-4095B2_02_12-Novartis-Zometa-App-11.htm. Accessed 2 February 2007.
22. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
23. Brooks JK, Gilson AJ, Sindler AJ, et al. Osteonecrosis of the jaws associated with use of risedronate: Report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103: 780-6.
24. Capsoni F, Longhi M, Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role. Arthritis Res Ther 2006;8:219.
25. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-related Osteonecrosis of the Jaws. J Oral Maxillofac Surg. 2007;65:369-76.
26. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005; 182:413-5.
27. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182:417-8.
28. Diego R, D'Orto O, Pagani D, et al. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:e1-5.
29. Magopoulos C, Karakinaris G, Telioudis Z, et al. Am J Otolaryngol 2007;28:158-63.
30. Clarke B, Boyette J, Vural E, et al. Bisphosphonate and jaw necrosis: the UMAS experience. Otolaryngol Head Neck Surg 2007;136:396-400.
31. Mortensen M, Lawson W, Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: presentation of seven cases and literature review. Laryngoscope 2007;117:30-4.
32. Rossi R, Dorto O, Agazzi A, et al. Bisphosphonate-vascular osteonecrosis of the jaws: medical or surgical approach? [Abstract]. J Craniomaxillofac Surg 2006;34:34.
33. Merigo E, Manfredi M, Meleti M, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 2006;77:109-17.
34. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.
35. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases [Letter]. Oral Oncol 2006;42:327-9.
36. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol 2005;34:120-3.
37. Miglioratti CA, Shubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
38. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 2005;136: 1675-81.
39. Pires FR, Miranda A, Cardoso ES, et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 2005;11:365-9.
40. Estilo CS, Van Poznak CH, Williams T, et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study [Abstract]. Proc Am Soc Clin Oncol. 2004;22:750.
41. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
42. Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-60.
43. Thakkar SG, Isada C, Smith J, et al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 2006;23:51-6.
44. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 2005;23:8219-24.
45. Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002;(3): CD003188.
46. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14: 1399-405.
47. American dental association council on scientific affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137: 1144-50.
48. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the new generation bisphosphonates. Laryngoscope 2006;116:115-20.